University of Virginia
Welcome,         Profile    Billing    Logout  
 1080 Trials 
2934 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
O'Neill, Brian P
HOVER, NCT02339974: Heterotopic Implantation of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation

Active, not recruiting
3
6
US
Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava
Henry Ford Health System
Tricuspid Regurgitation
12/24
12/24
PACE-NODES, NCT05613023: A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

Recruiting
3
1128
Europe, RoW
SBRT, SABR
Institute of Cancer Research, United Kingdom, Prostate Cancer UK
Prostate Cancer
06/28
06/30
NCT04551651: AppReminders - A Pilot Feasibility Trial of a Memory Aid App for People With Acquired Brain Injury

Recruiting
N/A
50
Europe
ApplTree, Google Calendar
NHS Greater Glasgow and Clyde, University of Glasgow, Chief Scientist Office of the Scottish Government
Acquired Brain Injury
09/21
12/22
ECP EFS, NCT04477603: Impella ECP Early Feasibility Study

Active, not recruiting
N/A
100
US
Impella ECP
Abiomed Inc.
High-risk Percutaneous Coronary Intervention
10/25
10/25
ACCESS MANTA, NCT05936996: Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

Recruiting
N/A
250
Canada, US
MANTA Vascular Closure Device
Essential Medical, Inc., Essential Medical LLC a subsidiary of Teleflex, Incorporated
Femoral Arteriotomy Closure
01/25
03/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
SHIELD, NCT06689839: Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Not yet recruiting
N/A
500
US
F2 Filter and Delivery System, Transcatheter Aortic Valve Replacement (TAVR)
EnCompass Technologies, Inc., Avania, Insight Medical Consulting
Aortic Stenosis Treated With TAVI, Aortic Diseases
07/26
10/26
VISTA-US, NCT05848284: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( )

Recruiting
N/A
30
US
VDyne Transcatheter Tricuspid Valve Replacement System, VDyne System, VDyne Tricuspid System, VDyne Valve System, VDyne Valve
VDyne, Inc.
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
11/25
11/30
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
CORRAL-AF, NCT04684212: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

Not yet recruiting
N/A
2931
US
LAmbre PlusTM Left Atrial Appendage Closure System, LAmbre device, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa), OAC
Brian O'Neill MD, Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
12/29
12/34
Fadul, Camilo E
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease

Active, not recruiting
3
242
Canada, US
Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/26
03/28
NCT03344250: Phase I EGFR BATs in Newly Diagnosed Glioblastoma

Active, not recruiting
1
18
US
EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
University of Virginia
Glioblastoma, Glioblastoma Multiforme
12/21
12/24
Slingluff, Craig L
MEL60, NCT02126579: Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Completed
1/2
50
US
Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod, IFA
Craig L Slingluff, Jr, University of Virginia
Melanoma, Metastatic Melanoma, Mucosal Melanoma
11/19
05/21
Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed
1/2
33
US
6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma
01/24
01/24
Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed
1/2
22
US
6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma, Ocular Melanoma, Uveal Melanoma
03/24
03/24
AM-003, NCT04116320: Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Active, not recruiting
1
5
US
Echopulse, Focused Ultrasound Ablation, FUSA, Poly ICLC, Hiltonol, Standard of Care PD-1 Therapy
Craig L Slingluff, Jr, Theraclion
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
02/24
02/24
Mel61, NCT02382549: A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Terminated
1
8
US
BRAF inhibitor, 6MHP, 6 melanoma helper peptide vaccine, MEK inhibitor
Craig L Slingluff, Jr, National Cancer Institute (NCI)
Melanoma
02/22
02/22
EXCILYNT, NCT05839912: Excision of Lymph Node Trial () (Mel69)

Recruiting
N/A
66
US
Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Craig L Slingluff, Jr
Melanoma
09/28
09/28
Laughlin, Mary J
NCT04083170: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Terminated
2
1
US
Fludarabine, 118218, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Thiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thiofosfamide, Thio-Tepa, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, Triethylene thiophosphoramide, Triethylenethiophosphoramide, TSPA, WR 45312, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation, Dilanubicel, Allogeneic UCB-derived Hematopoietic Stem and Progenitor Cells NLA101, Allogeneic Umbilical Cord Blood-derived HSPCs NLA101, NLA101
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia
11/22
11/22
McCarthy, Philip L
CALGB-100104, NCT00114101: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Checkmark Data presentation from CALGB 100104 study for NDMM at ASCO
Jun 2017 - Jun 2017: Data presentation from CALGB 100104 study for NDMM at ASCO
Checkmark P3 data
May 2012 - May 2012: P3 data
Active, not recruiting
3
460
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Placebo Administration
National Cancer Institute (NCI)
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
12/12
02/25
NCT03333486: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Active, not recruiting
2
31
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation
Roswell Park Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
08/23
08/24
NCT03925532: Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Completed
2
30
US
Denosumab, AMG 162, AMG-162, Prolia, Xgeva
Roswell Park Cancer Institute, Amgen
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
11/22
11/22
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Recruiting
2
300
US
Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
07/24
07/24
NCT02650986: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Active, not recruiting
1/2
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes, TGFbDNRII-transduced Autologous TILs
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
03/21
07/32
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Dreicer, Robert
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
CHAARTED2, NCT03419234: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Active, not recruiting
2
223
US
Abiraterone Acetate, CB7630, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Laboratory Biomarker Analysis, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
09/25
04/26
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Active, not recruiting
1/2
144
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
08/26
04/27
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Manning, Carol A
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting
3
187
Canada, US
Escitalopram, Lexapro, Placebo, non-applicable
JHSPH Center for Clinical Trials, National Institute on Aging (NIA)
Dementia
04/24
05/25
NCT05063851: The Use of Memantine for Prevention of Alzheimer's Disease

Recruiting
2
32
US
Memantine Hydrochloride Tablets, Placebo
University of Virginia
Alzheimer Disease
12/25
12/25
NCT05131217: Effects of Acute Exercise Intensity on Cerebral Blood Flow and Cognitive Function in Older Adults

Completed
N/A
13
US
Acute bout of Continuous Moderate Intensity Exercise, Acute bout of High Intensity Interval Training, HIIT, Control, Rest
University of Virginia
Aging Well
05/23
05/23
NCT03512301: CAMCI: Advancing the Use of Computerized Screening in Healthcare

Completed
N/A
773
US
CAMCI, CAMCI task battery
Psychology Software Tools, Inc., National Institute on Aging (NIA)
Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
05/23
05/23
PACE-DLB, NCT04829656: The Study

Active, not recruiting
N/A
300
US
University of Florida, National Institute on Aging (NIA)
Dementia With Lewy Bodies
02/25
05/25
NCT04495686: An Innovative Supportive Care Model for Dementia and Traumatic Brain Injury

Active, not recruiting
N/A
171
US
Telehealth-delivered Care Coordination Program
University of Virginia, Congressionally Directed Medical Research Programs
Dementia, Mixed, Dementia Mild, Dementia Moderate, Traumatic Brain Injury, Alzheimer Disease
09/25
09/25
Evans, William S
NCT05653440: Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia

Recruiting
2
30
US
Accuracy-maximized condition, Effort-maximized condition, Effort-accuracy balanced condition
University of Pittsburgh, University of Massachusetts, Amherst, National Institute on Deafness and Other Communication Disorders (NIDCD)
Aphasia, Stroke
01/27
01/28
NCT05653466: Adaptive Trial Scheduling in Naming Treatment for Aphasia

Recruiting
2
32
US
Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition
University of Pittsburgh, University of Massachusetts, Amherst, National Institute on Deafness and Other Communication Disorders (NIDCD)
Aphasia, Stroke
01/27
01/28
NCT02564484: iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy

Completed
N/A
137
US
St. Jude Children's Research Hospital, University of Chicago, National Cancer Institute (NCI)
Leukemia, Lymphoma
05/21
07/24
NCT04984239: Adapting Acceptance and Commitment Therapy for Stroke Survivors With Aphasia

Completed
N/A
20
US
Acceptance and Commitment Therapy for aphasia
University of Pittsburgh, University of Delaware, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Stroke, Aphasia
01/24
01/24
NCT05368480: Evaluating the Impact of Senior Companion Programs

Recruiting
N/A
1040
US
Senior Companion Program
William Evans, Health Association of Niagara County, Inc., Catholic Charities of Southeast Michigan, Georgia Southern University, The Evangelical Lutheran Good Samaritan Society, Positive Maturity, Inc.
Aging, Disabilities Multiple
12/25
12/25
NCT05428514: Evaluating the Impact of Emergency Maternity Housing

Recruiting
N/A
1048
US
Maternity Housing, Emergency Maternity Housing
University of Notre Dame, Bethlehem House, In My Shoes, Our Lady's Inn, USA, Aid for Women, Maggie's Place, USA
Housing Problems, Pregnancy Related
12/25
12/25
NCT05341830: Housing for Recovery Initiative

Not yet recruiting
N/A
2430
NA
Recovery housing
Adrienne Sabety, Ohio Recovery Housing, Ohio State University
Substance-related Disorders, Alcohol-related Disorders, Housing
03/26
03/26
Tiouririne, Nassima Ait-Daoud
NCT01182766: New Treatment for Alcohol and Nicotine Dependence

Active, not recruiting
2/3
294
US
Topiramate with brief behavioral enhancement therapy, Topamax, Placebo with brief behavioral enhancement therapy, sugar pill
University of Virginia, National Institute on Alcohol Abuse and Alcoholism (NIAAA), M.D. Anderson Cancer Center, University of California, San Diego
Alcohol Dependence, Nicotine Dependence
06/22
06/22
NCT03878316: Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

Completed
2
100
US
Instranasal Oxytocin
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol Misuse
10/23
10/23
NCT03120468: Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder

Active, not recruiting
1
16
US
Topiramate and N-Acetyl Cysteine, Topamax, Topiramate and Placebo, Topamax; Sugar Pill
Nassima Ait-Daoud Tiouririne
Alcoholism
01/21
01/21
NCT03969251: Transcranial Magnetic Stimulation (TMS) Treatment for Alcohol Use Disorder

Recruiting
N/A
20
US
Transcranial Magnetic Stimulation (rTMS), Sham (SS)
Nassima Ait-Daoud Tiouririne
Alcoholism
03/21
06/21
NCT03969238: Utilizing Helpline for Opioid Dependence Treatment

Recruiting
N/A
1000
US
Helpline
University of Virginia
Opioid Dependence
04/21
04/21
NCT03968237: Measures to Improve Outcomes After an Opioid Overdose

Recruiting
N/A
200
US
Buprenorphine/Naloxone, Belbuca, Probuphine, Narcan
Nassima Ait-Daoud Tiouririne
Opioid Overdose
06/21
06/21
NCT05857852: Low-Intensity Focused Ultrasound for Cocaine Use Disorder

Recruiting
N/A
30
US
Low-Intensity Focused Ultrasound, Sham LIFU device
University of Virginia
Cocaine Use Disorder, Cocaine Dependence, Cocaine Abuse, Ultrasound
03/25
03/25
Kindwall-Keller, Tamila
EQUATE, NCT04566328: Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the Trial

Recruiting
3
1450
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab and Hyaluronidase-fihj, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
12/27
12/27
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
SWOG S1608, NCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Active, not recruiting
2
95
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR 1202, TGR-1202, TGR1202, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/25
12/25
NCT02843347: STRIDE Biorepository

Recruiting
N/A
200
US
Blood draw
Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
07/23
07/23
Borish, Larry
NCT04380038: Viral Infection in Asthma (VIA) Study

Recruiting
4
60
US
Dupilumab Injectable Product, Rhinovirus
University of Virginia, Regeneron Pharmaceuticals
Asthma
05/25
01/26
NCT05094570: Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

Recruiting
4
20
US
Dupilumab Prefilled Syringe, DUPIXENT
University of Virginia, Regeneron Pharmaceuticals
Nasal Polyps, Staphylococcus Aureus
06/24
12/24
NCT03968211: Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

Completed
1
37
US
Salmonella typhi polysaccharide vaccine, Typhim Vi
University of Virginia, CSL Behring, Jeffrey Modell Foundation
Immune Deficiency
12/23
12/23
Lum, Lawrence G
NCT01658969: Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery

Recruiting
2
48
US
Doxorubicin, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Rubex, Cyclophosphamide, Cytoxan, CPM, CTX, Endoxan, Endoxana, Paclitaxel, Anzatax, Asotax, TAX, Taxol, Onxal™, Docetaxel, RP 56976, Taxotere, TXT, HER2Bi-armed activated T cells, laboratory biomarker analysis, therapeutic conventional surgery, Cytoxan®, Neosar®
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
06/15
11/15
Jones, Robert
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
332
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Checkmark From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Active, not recruiting
1b/2
149
Europe
AZD5363, Placebo, Fulvestrant
Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board
Estrogen Receptor Positive Breast Cancer
03/19
12/23
NCT05944237: HTL0039732 in Participants with Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Nxera Pharma UK Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
09/26
09/26
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study

Terminated
N/A
80
US
ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing
DePuy Orthopaedics
Osteoarthritis of the Knee
03/23
03/23
WAVE, NCT04540302: The Merit WRAPSODY AV Access Efficacy Study

Active, not recruiting
N/A
357
Europe, Canada, US, RoW
Merit WRAPSODY Endovascular Stent Graft, PTA
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
02/24
01/26
NCT05527483: Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Completed
N/A
32
US
[68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
University Hospitals Cleveland Medical Center
Prostate Cancer
10/22
10/22
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

Recruiting
N/A
5600
RoW
Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc
Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED
Malaria, Mosquito-Borne Disease
09/25
09/25
NCT04682665: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

Completed
N/A
81
Europe
Icosapent Ethyl Oral Capsule, Placebo
University of Leeds, National Cancer Institute (NCI), Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard School of Public Health (HSPH), University of Bradford
Colon Cancer Liver Metastasis
07/24
07/24
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
NCT06797193: Ultrasound with Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Not yet recruiting
N/A
60
US
Electronic Health Record Review, Liver Biopsy, Biopsy of Liver, Medical Device Usage and Evaluation, Perflutren Lipid Microspheres, Definity, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Mayo Clinic
Cirrhosis
01/27
01/27
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
N/A
6000
Europe
The Christie NHS Foundation Trust
Cancer
01/26
01/28
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

Recruiting
N/A
614
Europe
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
W.L.Gore & Associates
Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury
10/26
10/35
ACTRN12619000470190p: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study

Not yet recruiting
N/A
100
 
University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund
Liver Transplantation ; Anaesthetics
 
 
ACTRN12619000470190: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study

Not yet recruiting
N/A
100
 
University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund
Liver Transplantation , Anaesthetics
 
 
PINCER, NCT05650125: A Platform Study for solId orgaN CancERs

Recruiting
N/A
2000
Europe
Biosampling
University of Liverpool, Countess of Chester NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, Clatterbridge Centre for Oncology, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool Womens Hospital
Cancer, Surgery
01/30
01/30
Perlmutter, Joel
vUHDRS, NCT05748288: Development of the Virtual Unified Huntington's Disease Rating Scale

Completed
N/A
60
US
Huntington Study Group
Huntington Disease
05/23
05/23
NCT06084533: CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Enrolling by invitation
N/A
80
US
[11C]-CS1P1
Washington University School of Medicine
Parkinson Disease
02/29
02/29
NCT02763683: Investigations of Dementia in Parkinson Disease

Recruiting
N/A
320
US
PiB and VAT
Washington University School of Medicine, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA)
Parkinsons
03/30
03/30
NCT01052350: PET Imaging in Parkinson Disease Dementia

Active, not recruiting
N/A
320
US
Washington University School of Medicine
Parkinson's Disease
07/30
07/30
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
O'Connor, Owen A
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
Saver, Jeffrey
BRIDGE-TNK, NCT04733742: Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

Recruiting
2/3
544
RoW
rhTNK-tPA, TNKase, TNK-tPA, Endovascular treatment, intra-arterial treatment, interventional therapy
Xinqiao Hospital of Chongqing, CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
Stroke, Acute, Stroke, Ischemic
12/25
03/26
SEACOAST, NCT03737786: 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

Recruiting
2b
90
US
Tight control of end-tidal CO2 levels
University of California, Los Angeles, University of Southern California
Acute Stroke
01/25
01/25
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY)

Completed
N/A
100
US
BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group
BrainQ Technologies Ltd.
Ischemic Stroke
11/23
01/24
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

Recruiting
N/A
122
US
Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions
BrainQ Technologies Ltd.
Ischemic Stroke
07/26
10/26
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Recruiting
N/A
1060
US
Endovascular Stroke Treatment, Medical Management
University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai
Stroke, Stroke, Acute, Stroke, Ischemic
01/28
04/28
Cox, Daniel J
GEM, NCT05766735: Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: a Paradigm Shift in Lifestyle Modification

Recruiting
N/A
200
US
Routine Care + Glycemic Excursion Minimization (RC+GEM), Glucose Everyday Matters, Routine Care (RC)
Chiara Fabris, PhD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), DexCom, Inc.
Type 2 Diabetes
01/27
01/27
Gupta, Pankaj
NCT06470243: Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Recruiting
3
528
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabazitaxel, Jevtana, RPR-116258A, RPR116258A, Taxoid XRP6258, TXD258, XRP-6258, XRP6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
06/27
04/32
ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting
3
1210
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation, Inspection, Visual Inspection, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
12/25
12/25
NCT04155034: S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Recruiting
3
668
Canada, US, RoW
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prophylactic Cranial Irradiation, PCI
SWOG Cancer Research Network, National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
11/25
11/27
INNOVATE, NCT04134260: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting
3
586
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Hormone Therapy, Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal Therapy, hormone treatment, Hormones, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
11/26
11/26
S1914, NCT04214262: Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Active, not recruiting
3
480
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
05/28
05/28
 

Download Options